A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients with Advanced Malignancies
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
The primary objectives of this study are:
To evaluate the safety and tolerability of AMXI-5001
To describe any dose-limiting toxicity (DLT)
To determine the maximum tolerated dose (MTD) or highest protocol-defined doses (in the absence of exceeding the MTD)
To determine the Recommended Phase 2 Dose (RP2D) for AMXI-5001 as monotherapy
The secondary objectives of this study are:
To determine the preliminary efficacy of AMXI-5001 in tumors with BRCA mutation, either germ line or somatic, after progression on PARP inhibitors
To assess the pharmacokinetics of AMXI-5001
Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: a. Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition b. Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit c. Malignancy has progressed after standard therapy
Has evaluable or measurable tumor(s) in dose escalation by standard radiological and/or laboratory assessments as applicable to their malignancy.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub